机构：[1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, PekingUniversity Cancer Hospital & Institute, Beijing, China,[2]Department of Hematology, The Affiliated Cancer Hospital ofZhengzhou University and Henan Cancer Hospital, Zhengzhou, China,河南省肿瘤医院[3]Department of Oncology, Cancer Hospital Affiliatedto Guangzhou Medical University, Guangzhou, China,[4]Department of Lymphoma, Tianjin Medical University Cancer Instituteand Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-USCenter for Lymphoma and Leukemia Research, Tianjin, China,[5]Department of Hematology, Qilu Hospital, ShandongUniversity, Jinan, China.Shandong Provincial Key Laboratory of Immunohematology, Qilu Hospital, Shandong University,Jinan, China,[6]Department of Hematology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu ProvinceHospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China,江苏省人民医院[7]Department of Hematology,The First Affiliated Hospital of Nanchang University, Nanchang, China,[8]Department of Hematology, The First AffiliatedHospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China,[9]Lymphoma & Hematology Department, Tumor Hospital of Xiangya School of Medicine of Central South University,Changsha, China,[10]Department of Medical Oncology, Liaoning Cancer Hospital and Institute, Shenyang, China,[11]Department of Hematology, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, China,[12]Department of Medical Oncology, Second Affiliated Hospital of Dalian Medical University, Dalian, China,[13]Department ofHematology, Shanghai First People’s Hospital, Shanghai Jiaotong University, Shanghai, China,[14]Department of MedicalOncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China,四川大学华西医院[15]Department of Medical Oncology,Heilongjiang Provincial Hospital, Harbin, China,[16]Department of Hematology, The Fourth Hospital of Hebei MedicalUniversity, Shijiazhuang, China,[17]Clinical Oncology Department, Weifang People’s Hospital, Weifang, China,[18]Institute ofHematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China,华中科技大学同济医学院附属协和医院[19]Third Department of Medical Oncology, Shaanxi Provincial Cancer Hospital, Xi’an, China,[20]Department of Hematology,Shanghai Tongren Hospital, Shanghai, China,[21]Department of Hematology, The Affiliated Hospital of Qingdao University,Qingdao, China,[22]Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China,[23]Department of Hematology, The Third Affiliated Hospital of Suzhou University, The First People’s Hospital of Changzhou,Changzhou, China,[24]Akeso Biopharma Co., Ltd., Zhongshan, China
第一作者机构：[1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, PekingUniversity Cancer Hospital & Institute, Beijing, China,
通讯作者：
推荐引用方式(GB/T 7714)：
Song Yuqin,Zhou Keshu,Jin Chuan,et al.Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201)[J].FRONTIERS IN ONCOLOGY.2022,12:doi:10.3389/fonc.2022.925236.
APA：
Song Yuqin,Zhou Keshu,Jin Chuan,Qian Zhengzi,Hou Ming...&Zhu Jun.(2022).Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201).FRONTIERS IN ONCOLOGY,12,
MLA：
Song Yuqin,et al."Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201)".FRONTIERS IN ONCOLOGY 12.(2022)
